Martin S. Tallman

TL;DR: High clinical activity of quizartinib at the evaluated doses is consistent with previous reports with an improved safety profile, and need to dose-escalate more than half of patients who received quizartInib 30 mg also supports further investigation of treatment with quizart inib 60 mg/day.

TL;DR: The results indicate the need for clinical trials to test the efficacy of drugs that inhibit the FLT3 RTK in this subset of patients with T-ALL, which coexpress CD117/KIT and cytoplasmic CD3.

TL;DR: Four different rearrangements of the erythropoietin receptor gene EPOR in Philadelphia chromosome-like (Ph-like) ALL result in truncation of the cytoplasmic tail of EPOR at residues similar to those mutated in primary familial congenital polycythemia, with preservation of the proximal tyrosine essential for receptor activation and loss of distal regulatory residues.

TL;DR: The FACT-Leu scale is a valid, reliable, and efficient measure of leukemia-specific health-related quality of life for acute and chronic disease.

TL;DR: CRLF2-d and IGH@-t represent distinct subtypes of adolescent and adult ALL and deletions of key B-cell differentiation and cell cycle control genes are highly prevalent but vary in frequency by cytogenetic subgroup.